No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 12, 2025 -- Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery.
Vasundhara Mathur, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a retrospective cohort study to examine the long-term outcomes of neoadjuvant semaglutide before MBS. Patients who received semaglutide before MBS from 2017 to 2024 were matched 1:1 with patients who did not receive semaglutide before MBS using nearest-neighbor propensity score matching (182 patients and 182 controls).
The researchers found that at postoperative months 6, 9, and 12, total weight loss (TWL) was lower for patients who received preoperative semaglutide than controls (median 12-month TWL: 21.0 versus 26.0 percent). For patients who received semaglutide, combined multimodality TWL was higher at postoperative month 3 but did not differ thereafter. Patients receiving preoperative semaglutide versus controls had similar median hemoglobin A1c levels before MBS and one year after MBS. Furthermore, both cohorts had a similar number of patients with diabetes remission at postoperative year 1. Early major postoperative complications did not differ significantly across cohorts.
"This study showed neoadjuvant semaglutide did not confer benefits for weight loss, diabetes remission, or MBS safety," the authors write.
Several authors disclosed ties to the biopharmaceutical industry; one author has three patents pending.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.